

In the Claims:

Claims 1-35. (Cancelled)

36. (Currently Amended) A kit for use in preparing a recombinant adenovirus, said kit comprising:

- (a) ~~a first vector comprising~~ an adenoviral genome **vector** comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein each of said first, second and third restriction endonuclease sites are: (i) different, (ii) do not occur in the corresponding wild type adenoviral genome and (iii) are located in said E gene deletion region; and
- (b) first, second and third restriction endonucleases that correspond to said first, second and third restriction endonuclease sites.

37. (Currently Amended) The kit according to Claim 36, wherein said **first adenoviral genome** vector is a plasmid.

38. (Currently Amended) The kit according to Claim 36, wherein said kit further comprises a shuttle vector comprising a multiple cloning site flanked by said first and ~~second~~ **third** restriction endonuclease sites.

39. (Original) The kit according to Claim 38, wherein said shuttle vector is a plasmid.

40. (Original) The kit according to Claim 36, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.

Please enter the following new claims:

41. **(New)** The kit according to Claim 36, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.
42. **(New)** The kit according to Claim 36, wherein said first, second and third restriction endonucleases are selected from the group consisting of I-CeuI, PI-SceI and SwaI.
43. **(New)** The kit according to Claim 36, wherein said adenoviral genome is an AD type 5 genome.
44. **(New)** A kit for use in preparing a recombinant adenovirus, said kit comprising:
- (a) an adenoviral genome vector comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein each of said first, second and third restriction endonuclease sites are: (i) different, (ii) do not occur in the corresponding wild type adenoviral genome and (iii) are located in said E gene deletion region;
 - (b) first, second and third restriction endonucleases that correspond to said first, second and third restriction endonuclease sites; and
 - (c) a shuttle vector comprising a multiple cloning site flanked by said first and third restriction endonuclease sites.
45. **(New)** The kit according to Claim 44, wherein said adenoviral genome vector is a plasmid.
46. **(New)** The kit according to Claim 44, wherein said shuttle vector is a plasmid.

47. **(New)** The kit according to Claim 44, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.
48. **(New)** The kit according to Claim 44, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.
49. **(New)** The kit according to Claim 44, wherein said first, second and third restriction endonucleases are selected from the group consisting of I-CeuI, PI-SceI and SwaI.
50. **(New)** The kit according to Claim 44, wherein said adenoviral genome is an AD type 5 genome.
51. **(New)** A kit for use in preparing a recombinant adenovirus, said kit comprising:
- (a) an adenoviral genome vector comprising an E gene deletion region and first, second and third restriction endonuclease sites, wherein said first restriction endonuclease site is I-CeuI, said second restriction endonuclease site is SwaI and said third restriction endonuclease site is PI-SceI;
 - (b) I-CeuI;
 - (c) PI-SceI;
 - (d) SwaI; and
 - (e) a shuttle vector comprising a multiple cloning site flanked by I-CeuI and PI-SceI restriction endonuclease sites.
52. **(New)** The kit according to Claim 51, wherein said adenoviral genome vector is a plasmid.

53. **(New)** The kit according to Claim 51, wherein said shuttle vector is a plasmid.
54. **(New)** The kit according to Claim 51, wherein said kit further comprises a cell that is transcomplementing for any inactivated E genes of said E gene region with said ligation product.
55. **(New)** The kit according to Claim 51, wherein said E gene deletion region is characterized by having a deletion of at least one of an E1, E3 and E4 region.
56. **(New)** The kit according to Claim 51, wherein said adenoviral genome is an AD type 5 genome.